Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Obeticholic Acid Market?

In recent years, a swift expansion can be seen in the market size of Obeticholic Acid. It’s projected to rise from $0.9 billion in 2024 to $1.01 billion in 2025, marking a compound annual growth rate (CAGR) of 12.3%. The propulsion in growth during the historic period can be accredited to an increased prevalence of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). Factors such as the development of healthcare structure in burgeoning markets, acceleration in liver disease diagnostic procedures and screenings, heightened healthcare spending, and funding in liver disease research also contributed.

In the coming years, the obeticholic acid market is projected to undergo rapid expansion. It is anticipated to swell to “$1.64 billion by 2029 with a compound yearly growth rate (CAGR) of 12.8%. This surge during the forecast period can be traced back to the escalating prevalence of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), the growing call for cutting-edge treatments for liver diseases, increasing consciousness about liver diseases and their corresponding treatments, enhancements in global healthcare reach in emerging markets, and elevated awareness pertaining to liver diseases and their treatment options. Key trends during the forecast period will involve the adoption of NASH treatment, forging partnerships and alliances for additional development, the incorporation of digital health tools for tracking and adherence, a shift towards non-alcoholic fatty liver disease (NAFLD) treatment, the advent in liver disease biomarkers, and diagnostic technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

Which Growth Drivers Are Shaping The Obeticholic Acid Market Outlook?

The escalating occurrence of liver conditions is set to drive the expansion of the obeticholic acid market in the future. Conditions affecting the liver’s performance are increasing due to indulgence in excessive alcohol drinking, which can trigger liver inflammation, cirrhosis, and liver failure by harming liver cells and compromising the organ’s effectiveness. Obeticholic acid benefits individuals with liver disease by activating the farnesoid X receptor (FXR). This activation results in reduced bile acid accumulation, decreased liver inflammation, and slowed progression of fibrosis, which collectively improve the liver’s function. For example, the Office for Health Improvement and Disparities, a UK government department, reported in December 2024 that there was a 3.6% increase in premature deaths due to alcoholic liver disease in 2023, totalling 5,984, an increase from 5,776 in 2022. As a result, the escalating incidence of liver diseases is fuelling the expansion of the obeticholic acid market.

Which Segment Accounts For The Largest Share In The Obeticholic Acid Market?

The obeticholic acid market covered in this report is segmented –

1) By Product Type: Tablets, Capsules, Other Product Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

Subsegments:

1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets

2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules

3) By Other Product Types: Oral Suspensions, Injectable Formulations

Which Long-Term Trends Will Play A Crucial Role In The Obeticholic Acid Market?

Leading entities in the obeticholic acid industry are introducing unique solutions like the farnesoid X receptor (FXR) agonists to enhance the treatment of liver diseases and boost patient results. A farnesoid X receptor (FXR) agonist activates the FXR, a nuclear receptor that plays a key role in the regulation of bile acid metabolism, inflammation, and fibrosis in the liver. The use of farnesoid X receptor (FXR) agonists assist in improving liver functions and is utilized in treating diseases such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For example, in February 2024, Intercept Pharmaceuticals Inc., an American biopharmaceutical corporation, confirmed that their supplemental New Drug Application (sNDA) for Ocaliva for treating patients diagnosed with primary biliary cholangitis (PBC) was approved by the U.S. Food and Drug Administration (FDA). The FDA’s green light to the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) represents a regulatory advancement towards validating its clinical advantages in treating PBC.

Which Companies Hold A Competitive Edge In The 563 Market?

Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy’s Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

Which Region Is Forecasted To Lead The Obeticholic Acid Market In The Coming Years?

North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model